ORGO Should I Buy

Truist initiated coverage of Organogenesis with a Hold rating and $3 price target. Reimbursement changes are driving structural shifts across care settings in 2026 and a shakeout in the space could benefit Organogenesis as smaller skin substitute players exit the market due to unfavorable economics, the analyst tells investors. However, the firm sees limited near-term revenue upside, noting that the company's recently lowered guidance contemplates a worse decline in 2026 than previously expected.